PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, New England Journal of Medicine, vol.372, issue.26, pp.2509-2520, 2015. ,
Mutational landscape determines sensitivity to PD-1 blockade in non?small cell lung cancer, Science, vol.348, issue.6230, pp.124-128, 2015. ,
PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.515, issue.7528, pp.568-571, 2014. ,
, J Immunother Cancer, 2020.
PD-1 Blockade Expands Intratumoral Memory T Cells, Cancer Immunology Research, vol.4, issue.3, pp.194-203, 2016. ,
Classifying Cancers Based on T-cell Infiltration and PD-L1, Cancer Research, vol.75, issue.11, pp.2139-2145, 2015. ,
Phase I Study of Single-Agent Anti?Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates, Journal of Clinical Oncology, vol.28, issue.19, pp.3167-3175, 2010. ,
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab, Journal of Clinical Oncology, vol.32, issue.10, pp.1020-1030, 2014. ,
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape, Science Translational Medicine, vol.4, issue.127, pp.127ra37-127ra37, 2012. ,
Safety, Activity, and Immune Correlates of Anti?PD-1 Antibody in Cancer, New England Journal of Medicine, vol.366, issue.26, pp.2443-2454, 2012. ,
PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis, Critical Reviews in Oncology/Hematology, vol.100, pp.88-98, 2016. ,
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy, Science, vol.350, issue.6264, pp.1084-1089, 2015. ,
Cancer and the gut microbiota: An unexpected link, Science Translational Medicine, vol.7, issue.271, pp.271ps1-271ps1, 2015. ,
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade, Nature Immunology, vol.20, issue.3, pp.326-336, 2019. ,
Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma, Cell, vol.176, issue.4, pp.775-789.e18, 2019. ,
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade, Nature Medicine, vol.24, issue.7, pp.994-1004, 2018. ,
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade, Cancer Discovery, vol.6, issue.8, pp.827-837, 2016. ,
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response, Nature, vol.545, issue.7652, pp.60-65, 2017. ,
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma, Nature Medicine, vol.25, issue.3, pp.454-461, 2019. ,
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation, Immunity, vol.44, issue.5, pp.989-1004, 2016. ,
Emergence of High-Avidity Melan-A?Specific Clonotypes as a Reflection of Anti?PD-1 Clinical Efficacy, Cancer Research, vol.77, issue.24, pp.7083-7093, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01636933
TIGIT and PD-1 impair tumor antigen?specific CD8+ T cells in melanoma patients, Journal of Clinical Investigation, vol.125, issue.5, pp.2046-2058, 2015. ,
Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase, Journal of Investigative Dermatology, vol.136, issue.1, pp.255-263, 2016. ,
TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy, Immunological Reviews, vol.276, issue.1, pp.112-120, 2017. ,
TCR-ligand dissociation rate is a robust and stable biomarker of CD8+ T cell potency, JCI Insight, vol.2, issue.14, 2017. ,
T Cell Factor 1-Expressing Memory-like CD8+ T Cells Sustain the Immune Response to Chronic Viral Infections, Immunity, vol.45, issue.2, pp.415-427, 2016. ,
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy, Nature, vol.537, pp.417-438, 2016. ,
Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection, Nature, vol.537, issue.7620, pp.412-416, 2016. ,
CXCR5+ follicular cytotoxic T cells control viral infection in B cell follicles, Nature Immunology, vol.17, issue.10, pp.1187-1196, 2016. ,
High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors, Journal of Experimental Medicine, vol.215, issue.10, pp.2520-2535, 2018. ,
Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy, Immunity, vol.50, issue.1, pp.195-211.e10, 2019. ,
Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy, Immunity, vol.50, pp.195-211, 2019. ,
A Portrait of CXCR5+ Follicular Cytotoxic CD8+ T cells, Trends in Immunology, vol.39, issue.12, pp.965-979, 2018. ,
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy, Journal of Clinical Oncology, vol.37, issue.9, pp.693-702, 2019. ,
Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy, Journal for ImmunoTherapy of Cancer, vol.6, issue.1, p.131, 2018. ,
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1?targeted therapy in lung cancer patients, Proceedings of the National Academy of Sciences, vol.114, issue.19, pp.4993-4998, 2017. ,
A Full GMP Process to Select and Amplify Epitope-Specific T Lymphocytes for Adoptive Immunotherapy of Metastatic Melanoma, Clinical and Developmental Immunology, vol.2013, pp.1-11, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-01727317
A scaling normalization method for differential expression analysis of RNA-seq data, Genome Biology, vol.11, issue.3, p.R25, 2010. ,
voom: precision weights unlock linear model analysis tools for RNA-seq read counts, Genome Biology, vol.15, issue.2, p.R29, 2014. ,
limma powers differential expression analyses for RNA-sequencing and microarray studies, Nucleic Acids Research, vol.43, issue.7, pp.e47-e47, 2015. ,
Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments, Statistical Applications in Genetics and Molecular Biology, vol.3, issue.1, pp.1-25, 2004. ,
Use of within-array replicate spots for assessing differential expression in microarray experiments, Bioinformatics, vol.21, issue.9, pp.2067-2075, 2005. ,
Camera: a competitive gene set test accounting for inter-gene correlation, Nucleic Acids Research, vol.40, issue.17, pp.e133-e133, 2012. ,
Molecular signatures database (MSigDB) 3.0, Bioinformatics, vol.27, issue.12, pp.1739-1740, 2011. ,
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade, Cell, vol.175, issue.4, pp.984-997.e24, 2018. ,
TCR Analyses of Two Vast and Shared Melanoma Antigen-Specific T Cell Repertoires: Common and Specific Features, Frontiers in Immunology, vol.9, p.9, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-01885141
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function, Cancer Cell, vol.26, issue.6, pp.923-937, 2014. ,
Rescue of exhausted CD8 T cells by PD-1?targeted therapies is CD28-dependent, Science, vol.355, issue.6332, pp.1423-1427, 2017. ,
Human Effector and Memory CD8+ T Cell Responses to Smallpox and Yellow Fever Vaccines, Immunity, vol.28, issue.5, pp.710-722, 2008. ,
T cell costimulatory receptor CD28 is a primary target for PD-1?mediated inhibition, Science, vol.355, issue.6332, pp.1428-1433, 2017. ,
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia, Nature Medicine, vol.24, issue.5, pp.563-571, 2018. ,
CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor, Clinical Cancer Research, vol.20, issue.1, pp.44-55, 2013. ,
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors, Journal of Clinical Investigation, vol.124, issue.5, pp.2246-2259, 2014. ,
Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor, Cancer Immunology Research, vol.4, issue.9, pp.734-743, 2016. ,
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors, Nature Communications, vol.9, issue.1, pp.2724-2737, 2018. ,
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates, Nature, vol.557, issue.7706, pp.575-579, 2018. ,
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity, Proceedings of the National Academy of Sciences, vol.114, issue.5, pp.E761-E770, 2017. ,
Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy, Immunity, vol.50, issue.6, pp.1498-1512.e5, 2019. ,
, J Immunother Cancer, 2020.
TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection, Nature, vol.571, issue.7764, pp.265-269, 2019. ,
TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion, Nature, vol.571, issue.7764, pp.211-218, 2019. ,
TOX is a critical regulator of tumour-specific T cell differentiation, Nature, vol.571, issue.7764, pp.270-274, 2019. ,
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response, Science Translational Medicine, vol.6, issue.254, pp.254ra128-254ra128, 2014. ,
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma, Nature Medicine, vol.24, issue.11, pp.1655-1661, 2018. ,
Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1?CD8+ Tumor-Infiltrating T Cells, Immunity, vol.50, issue.1, pp.181-194.e6, 2019. ,
Clonal replacement of tumor-specific T cells following PD-1 blockade, Nature Medicine, vol.25, issue.8, pp.1251-1259, 2019. ,
Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions, The Journal of Immunology, vol.186, issue.3, pp.1338-1342, 2011. ,
T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients, Clinical Cancer Research, vol.22, issue.12, pp.3057-3066, 2016. ,
Safety and Activity of Anti?PD-L1 Antibody in Patients with Advanced Cancer, New England Journal of Medicine, vol.366, issue.26, pp.2455-2465, 2012. ,
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response, Nature Medicine, vol.24, issue.10, pp.1550-1558, 2018. ,
Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction, eLife, vol.8, p.2930, 2019. ,
In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients, Cancers, vol.11, issue.9, p.1271, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02381188
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma, New England Journal of Medicine, vol.374, issue.26, pp.2542-2552, 2016. ,
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab, Cell, vol.171, issue.4, pp.934-949.e16, 2017. ,
Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma, Cancer Immunology Research, vol.7, issue.1, pp.77-85, 2018. ,
T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient, Cancer Immunology, Immunotherapy, vol.67, issue.11, pp.1767-1776, 2018. ,
Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma, OncoImmunology, vol.5, issue.9, p.e1204507, 2016. ,
Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy, JCI Insight, vol.3, issue.23, p.5838, 2018. ,
Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels, Journal for ImmunoTherapy of Cancer, vol.7, issue.1, p.43, 2019. ,
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy, Cancer Discovery, vol.8, issue.9, pp.1069-1086, 2018. ,
Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma, Nature Medicine, vol.26, issue.2, pp.193-199, 2020. ,
Peripheral T cell expansion predicts tumour infiltration and clinical response, Nature, vol.579, issue.7798, pp.274-278, 2020. ,
Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy, Nature Cancer, vol.1, issue.2, pp.210-221, 2020. ,